What is CRISPR Therapeutics's other commercial liabilities?

CRISPR Therapeutics (CRSP) reported other commercial liabilities of $74.93M in Q1 2026.

How has CRISPR Therapeutics's other commercial liabilities changed year-over-year?

CRISPR Therapeutics's other commercial liabilities decreased by 11.4% year-over-year, from $84.62M to $74.93M.

What is the long-term trend for CRISPR Therapeutics's other commercial liabilities?

Over 5 years (2020 to 2025), CRISPR Therapeutics's other commercial liabilities has grown at a 10.7% compound annual growth rate (CAGR), from $53.78M to $89.41M.

CRISPR Therapeutics CRSP Other Commercial Liabilities

Other Commercial Liabilities at other companies

Arrowhead ResearchARWR

——

RevvityRVTY

——

IncyteINCY

——

TEC

Bio-TechneTECH

——

Johnson & JohnsonJNJ

——

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

See full

Revenue$1.5M+68.6%

Operating income-$130.2M+12.2%

Net income-$122.9M+9.6%

EPS (diluted)-$1.28+19.0%

Balance sheet

See full

Cash & equivalents$423.3M+80.0%

Total debt$787.6M+259%

Total equity$1.8B-0.8%

Total assets$2.7B+25.8%

Cash flow

See full

Operating cash flow-$108.9M-102%

CapEx$504.0K+145%

Free cash flow-$109.4M-102%

Valuation

See full

Market cap$5.33B+56.4%

Enterprise value$5.69B+69.8%

P/S1,298.3×+1,208×

Profitability

See full

Operating margin-15,754.2%-17,253pp

Net margin-13,856.5%-15,058pp

FCF margin-9,777.6%-10,759pp

Returns & leverage

See full

Return on equity-31.2%+43.7pp

Debt / equity0.4×+0.3×

Current ratio18×+2.3×

Where this comes from

Reported directly by CRISPR Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about CRISPR Therapeutics's other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CRISPR Therapeutics's other commercial liabilities?: CRISPR Therapeutics (CRSP) reported other commercial liabilities of $74.93M in Q1 2026.
How has CRISPR Therapeutics's other commercial liabilities changed year-over-year?: CRISPR Therapeutics's other commercial liabilities decreased by 11.4% year-over-year, from $84.62M to $74.93M.
What is the long-term trend for CRISPR Therapeutics's other commercial liabilities?: Over 5 years (2020 to 2025), CRISPR Therapeutics's other commercial liabilities has grown at a 10.7% compound annual growth rate (CAGR), from $53.78M to $89.41M.